Most companies don’t think about pharmacovigilance until they’re forced to. A product gets approved, the first adverse event report lands in someone’s inbox, and suddenly, there’s a scramble to figure out:
- who owns the process,
- what the timelines are, and
- whether the spreadsheet built back in time is going to hold up under a regulatory inspection
A single tool or a single document can’t build a pharmacovigilance system. It’s built upon a combination of people, process, and technology. It should detect safety signals and help companies or patients avoid bigger problems. In this piece, we aim to walk you through how the PV system is actually built, from case processing to signal detection.
Case Processing and the Workflow
Case processing is the backbone of any PV system because the quality of cases sent to the database defines the future of signal detection and aggregate reports, and supports risk management plans. If the intake is accurate, the processes downstream can be smooth and trustworthy.
A typical case moves through five stages:
- Intake and triage
- Data entry
- Medical review
- Quality check
- Submission and follow-up
Building a real case depends on all the stages mentioned above, and one should close the gaps with clear ownership and clear deadlines, in addition to good intentions.
Signal Detection and Prioritization
Once cases are flowing cleanly into a safety database, the next step to look into is signal detection. It should evaluate accumulated data and spot patterns that a single case report could never reveal on its own.
A signal should warrant further investigation. From a regulatory perspective, a signal is all about information and should suggest:
- a new potentially causal association, or
- a new aspect of a known association, between a drug and an event
PV Signal detection runs on two (02) tracks:
- Quantitative methods
- Qualitative review
Based on the tracks, if something is flagged, it goes through validation with a query: is this a real signal or an artifact of reporting bias, a media-driven spike, or a coding error?
Once validation is done, prioritization surfaces. The surfaced signal measured against criteria like:
- seriousness of the event,
- strength of the evidence, and
- public health impact.
The high-priority signals go for formal signal evaluation. A deeper medical assessment is conducted, which may lead to label changes, an update to the risk management plan, or the initiation of critical studies.
Throughout the process, timing is very important. Hence, one should treat signal management as a continuous process rather than a periodic task. They should continuously review newly accumulated data on a rolling basis, so a signal won’t go unnoticed for months.
Whether you are a big pharma with a large number of product lines or a small biotech company, ensure your pharmacovigilance literature is in line with:
- global safety databases,
- dedicated epidemiology teams,
- In-house statisticians running EBGM calculations
While doing so, a few things can help you make it workable, such as:
- Outsource the critical activities.
- Ensure the in-house accountability.
- Leverage cloud-based safety databases.
- Practice realistic signal detection.
- Make sure everything is documented, even if it is simple.
Tools and Templates to Meet Time Criteria
Given the importance of time, setting up templates and upgrading tools strengthens the PV system. Organizations should scale up their workflows with:
- Safety databases (Oracle Argus, ArisGlobal LifeSphere, or Veeva Vault Safety handle case intake, etc.)
- Signal detection software
- SOP templates
- Aggregate reporting templates
- Risk management plan templates
However, none of these tools replace medical judgment, though they ensure judgment gets applied consistently.
For an organization setting up a PV system from scratch, the best starting point is simple. They must focus on fixing intake, standardizing processing, regularly reviewing signals, and documenting every step. Every case counts! Every regulatory perspective weighs. And a reliable process matters.